{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:06:34Z","timestamp":1775606794946,"version":"3.50.1"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cytogfr.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:44:01Z","timestamp":1708015441000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Targeting NKG2D\/NKG2DL axis in multiple myeloma therapy"],"prefix":"10.1016","volume":"76","author":[{"given":"Zhaoyun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9928-9224","authenticated-orcid":false,"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0268-960X(97)90004-7","article-title":"Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance","volume":"11","author":"Helfrich","year":"1997","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2005.05534.x","article-title":"Immunotherapy in multiple myeloma--possibility or probability?","volume":"130","author":"Harrison","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.02.001_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells\u2013a proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.02.001_bib4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/205796","article-title":"Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer","volume":"2014","author":"Romee","year":"2014","journal-title":"Scientifica"},{"issue":"9","key":"10.1016\/j.cytogfr.2024.02.001_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1027468","article-title":"Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis","volume":"4","author":"Guillerey","year":"2015","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.cytogfr.2024.02.001_bib7","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.exphem.2007.08.006","article-title":"Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model","volume":"35","author":"Alici","year":"2007","journal-title":"Exp. Hematol."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.02.001_bib8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/ni857","article-title":"NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation","volume":"3","author":"Gilfillan","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fimmu.2012.00299","article-title":"Human NKG2D-ligands: cell biology strategies to ensure immune recognition","volume":"3","author":"Fernandez-Messina","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib10","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.2741\/2939","article-title":"Soluble NKG2D ligands: prevalence, release, and functional impact","volume":"13","author":"Salih","year":"2008","journal-title":"Front. Biosci."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.02.001_bib11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3324\/haematol.2009.008318","article-title":"NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies","volume":"94","author":"Espinoza","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/85311","article-title":"Crystal structure of the murine NK cell-activating receptor NKG2D at 1.95 A","volume":"2","author":"Wolan","year":"2001","journal-title":"Nat. Immunol."},{"issue":"5428","key":"10.1016\/j.cytogfr.2024.02.001_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1126\/science.285.5428.730","article-title":"An activating immunoreceptor complex formed by NKG2D and DAP10","volume":"285","author":"Wu","year":"1999","journal-title":"Science"},{"issue":"5428","key":"10.1016\/j.cytogfr.2024.02.001_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.cytogfr.2024.02.001_bib15","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni858","article-title":"Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D","volume":"3","author":"Diefenbach","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib16","doi-asserted-by":"crossref","unstructured":"S.G. Ward, CD28: A Signalling Perspective, Biochem J 318 ( Pt 2)(Pt 2) (1996) 361-377.","DOI":"10.1042\/bj3180361"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib17","first-page":"169","article-title":"CD28 costimulatory molecule--expression, structure and function","volume":"50","author":"Bocko","year":"2002","journal-title":"Arch. Immunol. Ther. Exp."},{"issue":"6925","key":"10.1016\/j.cytogfr.2024.02.001_bib18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature01441","article-title":"CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes","volume":"421","author":"Janssen","year":"2003","journal-title":"Nature"},{"issue":"5617","key":"10.1016\/j.cytogfr.2024.02.001_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.1082305","article-title":"Requirement for CD4 T cell help in generating functional CD8 T cell memory","volume":"300","author":"Shedlock","year":"2003","journal-title":"Science"},{"issue":"5617","key":"10.1016\/j.cytogfr.2024.02.001_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.1083317","article-title":"Defective CD8 T cell memory following acute infection without CD4 T cell help","volume":"300","author":"Sun","year":"2003","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.02.001_bib21","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/ijc.26191","article-title":"Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction","volume":"131","author":"Andre","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.02.001_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1074-7613(00)80222-8","article-title":"Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice","volume":"12","author":"Cerwenka","year":"2000","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.cytogfr.2024.02.001_bib23","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.4049\/jimmunol.167.10.5527","article-title":"NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment","volume":"167","author":"Roberts","year":"2001","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.02.001_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ni1524","article-title":"NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway","volume":"8","author":"Horng","year":"2007","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib25","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4049\/jimmunol.1300670","article-title":"NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase","volume":"191","author":"Wensveen","year":"2013","journal-title":"J. Immunol."},{"issue":"24","key":"10.1016\/j.cytogfr.2024.02.001_bib26","doi-asserted-by":"crossref","first-page":"9149","DOI":"10.1128\/MCB.20.24.9149-9161.2000","article-title":"Pleiotropic contributions of phospholipase C-gamma1 (PLC-gamma1) to T-cell antigen receptor-mediated signaling: reconstitution studies of a PLC-gamma1-deficient Jurkat T-cell line","volume":"20","author":"Irvin","year":"2000","journal-title":"Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.02.001_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.02.001_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1471-4906(01)01960-3","article-title":"MICA and MICB genes: can the enigma of their polymorphism be resolved?","volume":"22","author":"Stephens","year":"2001","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1183\/09031936.00096407","article-title":"NKG2D-dependent effector function of bronchial epithelium-activated alloreactive T-cells","volume":"32","author":"Kraetzel","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2004.06.018","article-title":"A direct role for NKG2D\/MICA interaction in villous atrophy during celiac disease","volume":"21","author":"Hue","year":"2004","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.02.001_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1600-0714.2007.00539.x","article-title":"An association between the MICA-A5.1 allele and an increased susceptibility to oral squamous cell carcinoma in Japanese patients","volume":"36","author":"Tamaki","year":"2007","journal-title":"J. Oral. Pathol. Med"},{"key":"10.1016\/j.cytogfr.2024.02.001_bib32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fgene.2020.00511","article-title":"MICA ( *)012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer","volume":"11","author":"Ding","year":"2020","journal-title":"Front. Genet."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.02.001_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41435-018-0044-x","article-title":"MICA and NKG2D variants as risk factors in spondyloarthritis: a case-control study","volume":"20","author":"Fechtenbaum","year":"2019","journal-title":"Genes Immun."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib34","first-page":"1","article-title":"MIC genes: from genetics to biology","volume":"76","author":"Bahram","year":"2000","journal-title":"Adv. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.0960-7420.2001.00275.x","article-title":"Further polymorphism of the MICA gene","volume":"29","author":"Perez-Rodriguez","year":"2002","journal-title":"Eur. J. Immunogenet."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.02.001_bib36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1523-1747.2002.01700.x","article-title":"Expression of stress-induced MHC class I related chain molecules on human melanoma","volume":"118","author":"Vetter","year":"2002","journal-title":"J. Invest Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/geno.2001.6673","article-title":"A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3","volume":"79","author":"Radosavljevic","year":"2002","journal-title":"Genomics"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.02.001_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2567.2012.03625.x","article-title":"The molecular determinants of CD8 co-receptor function","volume":"137","author":"Cole","year":"2012","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.02.001_bib39","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.humimm.2013.01.030","article-title":"RAET1\/ULBP alleles and haplotypes among Kolla South American Indians","volume":"74","author":"Cox","year":"2013","journal-title":"Hum. Immunol."},{"issue":"21","key":"10.1016\/j.cytogfr.2024.02.001_bib40","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1073\/pnas.0502439102","article-title":"The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure","volume":"102","author":"Garrity","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","article-title":"Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a\u00a0novel therapeutic strategy","volume":"80","author":"Tewari","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.02.001_bib42","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1517\/14728222.12.8.1021","article-title":"Grb2 signaling in cell motility and cancer","volume":"12","author":"Giubellino","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.cytogfr.2024.02.001_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","article-title":"NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy","volume":"28","author":"Guerra","year":"2008","journal-title":"Immunity"},{"issue":"13","key":"10.1016\/j.cytogfr.2024.02.001_bib44","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1084\/jem.20120565","article-title":"RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry","volume":"209","author":"Jung","year":"2012","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/path.5097","article-title":"Integrating the DNA damage and protein stress responses during cancer development and treatment","volume":"246","author":"Gorgoulis","year":"2018","journal-title":"J. Pathol."},{"issue":"53","key":"10.1016\/j.cytogfr.2024.02.001_bib46","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1038\/sj.onc.1203015","article-title":"Regulation of p53 in response to DNA damage","volume":"18","author":"Lakin","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2024.02.001_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","article-title":"Regulation of ligands for the NKG2D activating receptor","volume":"31","author":"Raulet","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.02.001_bib48","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ni.1642","article-title":"Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D","volume":"9","author":"Stern-Ginossar","year":"2008","journal-title":"Nat. Immunol."},{"issue":"7768","key":"10.1016\/j.cytogfr.2024.02.001_bib49","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cytogfr.2024.02.001_bib50","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nsmb.2792","article-title":"Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways","volume":"21","author":"Mattiroli","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"Pt 3","key":"10.1016\/j.cytogfr.2024.02.001_bib51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1042\/BST0360459","article-title":"Natural killer cell evasion by an E3 ubiquitin ligase from Kaposi's sarcoma-associated herpesvirus","volume":"36","author":"Thomas","year":"2008","journal-title":"Biochem. Soc. Trans."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.02.001_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1339854","article-title":"Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation","volume":"6","author":"Vyas","year":"2017","journal-title":"Oncoimmunology"},{"issue":"15","key":"10.1016\/j.cytogfr.2024.02.001_bib53","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1158\/0008-5472.CAN-07-6768","article-title":"Tumor-associated MICA is shed by ADAM proteases","volume":"68","author":"Waldhauer","year":"2008","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.02.001_bib54","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.4049\/jimmunol.0903789","article-title":"The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule a independent of a disintegrin and metalloproteinases","volume":"184","author":"Liu","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3389\/fimmu.2020.00447","article-title":"NKG2D ligand shedding in response to stress: role of ADAM10","volume":"11","author":"Zingoni","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.02.001_bib56","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1074\/jbc.M109.045906","article-title":"Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands","volume":"285","author":"Fernandez-Messina","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cellimm.2006.03.002","article-title":"Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression","volume":"239","author":"Song","year":"2006","journal-title":"Cell Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.02.001_bib58","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1084\/jem.20050994","article-title":"NKG2D function protects the host from tumor initiation","volume":"202","author":"Smyth","year":"2005","journal-title":"J. Exp. Med."},{"issue":"22","key":"10.1016\/j.cytogfr.2024.02.001_bib59","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1158\/1078-0432.CCR-09-0991","article-title":"NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting","volume":"15","author":"McGilvray","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.02.001_bib60","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.bjc.6602123","article-title":"Loss of nonclassical MHC molecules MIC-A\/B expression during progression of uveal melanoma","volume":"91","author":"Vetter","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.02.001_bib61","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4049\/jimmunol.1402643","article-title":"Genotoxic stress induces senescence-associated ADAM10-dependent release of NKG2D MIC ligands in multiple myeloma cells","volume":"195","author":"Zingoni","year":"2015","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib62","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ijc.21382","article-title":"Soluble MICA in malignant diseases","volume":"118","author":"Holdenrieder","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib63","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/000348949110000304","article-title":"Patterns of physical and sexual abuse of communicatively handicapped children","volume":"100","author":"Sullivan","year":"1991","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib64","article-title":"Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: dual role in cancer immunosurveillance","volume":"11","author":"Vulpis","year":"2022","journal-title":"J. Extra Vesicles"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.02.001_bib65","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00262-009-0807-3","article-title":"Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked","volume":"59","author":"von Lilienfeld-Toal","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.02.001_bib66","first-page":"922","article-title":"Study of NK cells dysfunction in multiple myeloma patients","volume":"36","author":"Han","year":"2015","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib67","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clim.2006.11.007","article-title":"Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients","volume":"123","author":"Rebmann","year":"2007","journal-title":"Clin. Immunol."},{"issue":"6383","key":"10.1016\/j.cytogfr.2024.02.001_bib68","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.aao0505","article-title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity","volume":"359","author":"Ferrari de Andrade","year":"2018","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.02.001_bib69","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.02.001_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1218105","article-title":"Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells","volume":"5","author":"Antonangeli","year":"2016","journal-title":"Oncoimmunology"},{"issue":"15","key":"10.1016\/j.cytogfr.2024.02.001_bib71","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.02.001_bib72","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3816\/CLM.2006.n.028","article-title":"Intermediate-dose melphalan (100 mg\/m2)\/bortezomib\/thalidomide\/dexamethasone and stem cell support in patients with refractory or relapsed myeloma","volume":"6","author":"Palumbo","year":"2006","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1016\/j.cytogfr.2024.02.001_bib73","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3389\/fimmu.2018.00926","article-title":"and soluble mica are associated with the progression of multiple myeloma","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.02.001_bib74","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1593\/neo.121236","article-title":"Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma","volume":"14","author":"Wu","year":"2012","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib75","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s11095-013-1231-0","article-title":"The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells","volume":"32","author":"Zhu","year":"2015","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.02.001_bib76","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib77","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","article-title":"Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition","volume":"180","author":"Hallett","year":"2008","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.02.001_bib78","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib79","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jrr\/rry005","article-title":"The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells","volume":"59","author":"Lee","year":"2018","journal-title":"J. Radiat. Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib80","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1264564","article-title":"p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells","volume":"6","author":"Soriani","year":"2017","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.02.001_bib81","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1400271","article-title":"Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1","volume":"193","author":"Soriani","year":"2014","journal-title":"J. Immunol."},{"issue":"14","key":"10.1016\/j.cytogfr.2024.02.001_bib82","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-04-4252","article-title":"Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate","volume":"65","author":"Armeanu","year":"2005","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib83","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","article-title":"NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cytogfr.2024.02.001_bib84","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1096\/fj.201600961RR","article-title":"Histone deacetylase inhibitor apicidin increases expression of the alpha-secretase ADAM10 through transcription factor USF1-mediated mechanisms","volume":"31","author":"Hu","year":"2017","journal-title":"FASEB J."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.02.001_bib85","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.4049\/jimmunol.1201426","article-title":"Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3","volume":"190","author":"Fionda","year":"2013","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.02.001_bib86","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-09-4540","article-title":"Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells","volume":"71","author":"Bedel","year":"2011","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.02.001_bib87","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cytogfr.2024.02.001_bib88","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1196\/annals.1391.012","article-title":"Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress","volume":"1113","author":"Workman","year":"2007","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.02.001_bib89","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.02.001_bib90","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/10428190500472123","article-title":"Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma","volume":"47","author":"Duus","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.02.001_bib91","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00280-007-0546-0","article-title":"IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells","volume":"61","author":"Patterson","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.02.001_bib92","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2010.08360.x","article-title":"Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers","volume":"152","author":"Richardson","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.02.001_bib93","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.4049\/jimmunol.0901797","article-title":"Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation","volume":"183","author":"Fionda","year":"2009","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.02.001_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017075","article-title":"Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types","volume":"7","author":"Lonez","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.02.001_bib96","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/PPO.0000000000000029","article-title":"NKG2D CARs as cell therapy for cancer","volume":"20","author":"Sentman","year":"2014","journal-title":"Cancer J."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.02.001_bib97","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.exphem.2008.04.010","article-title":"Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma","volume":"36","author":"Barber","year":"2008","journal-title":"Exp. Hematol."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.02.001_bib98","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/0008-5472.CAN-06-4047","article-title":"Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer","volume":"67","author":"Barber","year":"2007","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.02.001_bib99","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.4049\/jimmunol.1600769","article-title":"Mechanisms of acute toxicity in NKG2D chimeric antigen receptor T Cell-treated mice","volume":"197","author":"Sentman","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front. Pharm."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib101","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fimmu.2015.00195","article-title":"Utilizing chimeric antigen receptors to direct natural killer cell activity","volume":"6","author":"Hermanson","year":"2015","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.cytogfr.2024.02.001_bib102","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1158\/0008-5472.CAN-10-4179","article-title":"Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma","volume":"71","author":"Platonova","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.02.001_bib103","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1264562","article-title":"High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer","volume":"6","author":"Sun","year":"2017","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib104","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell Mol. Immunol."},{"issue":"Suppl 2","key":"10.1016\/j.cytogfr.2024.02.001_bib105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41409-019-0601-6","article-title":"Adoptive cell therapy using engineered natural killer cells","volume":"54","author":"Rezvani","year":"2019","journal-title":"Bone Marrow Transpl."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.02.001_bib106","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.02.001_bib107","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib108","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fimmu.2015.00097","article-title":"NKG2D ligands in tumor immunity: two sides of a coin","volume":"6","author":"Zhang","year":"2015","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.02.001_bib109","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2003-06-2125","article-title":"Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells","volume":"103","author":"Verneris","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cytogfr.2024.02.001_bib110","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1182\/blood-2011-04-346825","article-title":"Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the gammac cytokines and TGF-beta1","volume":"118","author":"Park","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2024.02.001_bib111","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3389\/fimmu.2019.02689","article-title":"Impairment of NKG2D-mediated tumor immunity by TGF-beta","volume":"10","author":"Lazarova","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.02.001_bib112","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.4049\/jimmunol.180.11.7338","article-title":"Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D","volume":"180","author":"Krockenberger","year":"2008","journal-title":"J. Immunol."},{"issue":"7229","key":"10.1016\/j.cytogfr.2024.02.001_bib113","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature07665","article-title":"Adaptive immune features of natural killer cells","volume":"457","author":"Sun","year":"2009","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.02.001_bib114","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1073\/pnas.0813192106","article-title":"Cytokine-induced memory-like natural killer cells","volume":"106","author":"Cooper","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"24","key":"10.1016\/j.cytogfr.2024.02.001_bib115","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cytogfr.2024.02.001_bib116","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cytogfr.2024.02.001_bib117","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/asheducation-2013.1.247","article-title":"Therapeutic applications: natural killer cells in the clinic","volume":"2013","author":"Miller","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.02.001_bib118","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000203610","article-title":"Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis","volume":"98","author":"Sawanobori","year":"1997","journal-title":"Acta Haematol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.02.001_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.32","article-title":"The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.02.001_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020226","article-title":"Alterations of NK cell phenotype in the disease course of multiple myeloma","volume":"13","author":"Pazina","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2024.02.001_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575609","article-title":"Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy","volume":"11","author":"Alfarra","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.02.001_bib122","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.0730640100","article-title":"Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells","volume":"100","author":"Castriconi","year":"2003","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961012400011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961012400011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T21:23:40Z","timestamp":1711401820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135961012400011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":122,"alternative-id":["S135961012400011X"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.02.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting NKG2D\/NKG2DL axis in multiple myeloma therapy","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}